GIP - gastric inhibitory polypeptide Gene

生物種: Homo sapiens

遺伝子タイプ: protein coding

遺伝子ID: 2695

About GIP

Cytogenetic location: 17q21.32 Genomic coordinates (GRCh38): 17:48,958,554-48,968,596 (from NCBI)

This gene has 1 transcript (splice variant) and 128 orthologues. Biased expression in duodenum (RPKM 96.0) and small intestine (RPKM 33.9).

Summary

This gene encodes an incretin hormone and belongs to the glucagon superfamily. The encoded protein is important in maintaining glucose homeostasis as it is a potent stimulator of Insulin secretion from pancreatic beta-cells following food ingestion and nutrient absorption. This gene stimulates Insulin secretion via its G protein-coupled receptor activation of adenylyl cyclase and other signal transduction pathways. It is a relatively poor inhibitor of gastric acid secretion. [provided by RefSeq, Jul 2008]

GIP Products (1)

mRNA	Protein	Name
NM_004123.3	NP_004114.1	gastric inhibitory polypeptide preproprotein

Gene Ontology

Molecular Function
Biological Process

Molecular Function GO Annotation	Evidence	参考文献	由来
enables gastric inhibitory polypeptide receptor binding	IPI IPI: Inferred from physical interaction	17715056	GOA
enables protein binding	IPI IPI: Inferred from physical interaction	17715056	GOA

Biological Process GO Annotation	Evidence	参考文献	由来
involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway	IDA IDA: Inferred from direct assay	26572091	GOA
involved in gastric inhibitory peptide signaling pathway	IDA IDA: Inferred from direct assay	26572091	GOA

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

GIP Protein Structure

Hormone_2

0
100
153 a.a.

Protein Preferred Names	Protein Names
gastric inhibitory polypeptide	glucose-dependent insulinotropic polypeptide

GIP Protein-protein interaction Information

Type	タンパク質名	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	参考文献
Intra	GIP	P09681	ADAMTSL4	Homo sapiens	Q6UY14-3	Validated Y2H	25416956
Intra	GIP	P09681	ADAMTSL4	Homo sapiens	Q6UY14-3	Y2H Array	25416956
Intra	GIP	P09681	SGTA	Homo sapiens	O43765	Y2H Prey Pooling	25416956
Intra	GIP	P09681	SGTA	Homo sapiens	O43765	Y2H Prey Pooling	32296183
Intra	GIP	P09681	SGTA	Homo sapiens	O43765	Y2H Array	32296183
Intra	GIP	P09681	SGTB	Homo sapiens	Q96EQ0	Y2H Prey Pooling	32296183
Intra	GIP	P09681	SGTB	Homo sapiens	Q96EQ0	Validated Y2H	32296183
Intra	GIP	P09681	SGTB	Homo sapiens	Q96EQ0	Y2H Array	32296183
Intra	GIP	P09681	NOTCH2NLA	Homo sapiens	Q7Z3S9	Y2H Prey Pooling	25416956

Cross: Cross-species interaction Intra: Intraspecies interaction

Recombinant GIP Proteins

製品番号	製品名	アクセッション番号	純度
HY-P74125A	GIP Protein, Human (HEK293, hFc)	NP_004114.1 (E22-Q93)	≥ 95%, as determined by reducing SDS-PAGE.

関連疾患

Diseases	Alias
Dumping Syndrome	Jejunal Syndrome Dumping Dumping Syndrome Postgastrectomy Syndromes Postgastric Surgery Syndrome Postgastrectomy Syndrome Post Cibal Syndrome Postgastrectomy Dumping Syndrome
Hyperglycemia
Adenosquamous Bile Duct Carcinoma	Bile Duct Adenosquamous Carcinoma
Type 2 Diabetes Mellitus	Insulin Resistance NIDDM Type 2 Diabetes Diabetes Mellitus, Non-Insulin-Dependent T2D Noninsulin-Dependent Diabetes Mellitus Diabetes Mellitus, Type Ii Maturity-Onset Diabetes Insulin Resistance, Severe, Digenic Diabetes Mellitus, Type 2 Diabetes Mellitus, Noninsulin-Dependent Diabetes Mellitus, Noninsulin-Dependent, Association With Diabetes Mellitus, Noninsulin-Dependent, Late Onset Hypertension, Insulin Resistance-Related, Susceptibility To Insulin Resistance, Susceptibility To Non-Insulin-Dependent Diabetes Mellitus Type Ii Diabetes Mellitus Adult-Onset Diabetes Mellitus Maturity-Onset Diabetes Mellitus Diabetes Mellitus Type 2 Type Ii Diabetes Type 2 Diabetes Mellitus, Susceptibility To Diabetes, Type 2 Diabetes Mellitus, Noninsulin-Dependent, Susceptibility To Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility To Diabetes Mellitus, Type 2, Susceptibility To Diabetes Mellitus, Noninsulin-Dependent, 2 Diabetes Mellitus, Type Ii, Susceptibility To Hypertension, Insulin Resistance-Related Adult-Onset Diabetes Aodm Diabetes Mellitus, Adult-Onset Diabetes Mellitus Type Ii Diabetes Mellitus Type 2, Susceptibility To Diabetes, Type Ii, Susceptibility To Diabetes Type 2 Diabetes Mellitus Adult Onset Diabetes Maturity Onset Diabetes Nonketotic Diabetes Non-Insulin Dependent Diabetes Mellitus T2dm - [Type 2 Diabetes Mellitus] Niddm - [Non Insulin Dependent Diabetes Mellitus] Dm2 Dm Type Ii Diabetic Type 2 Insulin Requiring Type 2 Diabetes Noninsulin Dependent Diabetes Non-Insulin-Dependent Diabetes Mellitus Without Complications Diabetes Due To Insulin Secretory Defect Diabetes Mellitus Due To Insulin Secretory Defect Non-Insulin-Dependent Diabetes Of The Young Senile Diabetes Nonketotic Hyperglycaemia Stable Diabetes
Gastroparesis	Gastroparesis Syndrome Delayed Gastric Emptying Gastric Atonia Gastroparalysis
Somatostatinoma	Somatostatin Cell Neoplasm Somatostatin Cell Tumour Ampullary Somatostatinoma Carcinoid Somatostatinoma Malignant Islet Cell Tumor Somatomedin-Secreting Carcinoid Somatostatin-Secreting Pancreatic Neoplasm Pancreatic Somatostatinoma Pancreatic Endocrine Carcinoma
Postgastrectomy Syndrome	Postgastrectomy Syndromes Postgastric Surgery Syndrome
Acth-Independent Macronodular Adrenal Hyperplasia	Acth-Independent Macronodular Adrenocortical Hyperplasia Adrenocorticotropic Hormone-Independent Macronodular Adrenal Hyperplasia Corticotropin-Independent Macronodular Adrenal Hyperplasia Cushing Syndrome Due To Macronodular Adrenal Hyperplasia AIMAH1 Aimah Massive Macronodular Adrenocortical Disease Mmad Primary Macronodular Adrenal Hyperplasia Cushing Syndrome, Adrenal, Due To Aimah Primary Bilateral Macronodular Adrenal Hyperplasia Acth-Independent Macronodular Adrenal Hyperplasia 1 Acth-Independent Cushing Syndrome Adrenal Cushing Syndrome Due To Aimah Acth-Independent Macronodular Adrenal Hyperplasia 2
Squamous Cell Bile Duct Carcinoma	Bile Duct Squamous Cell Carcinoma
Insulinoma	Islet Cell Adenoma Insulin-Producing Tumor Of Islet Cells Adenoma Islet Cell Islet Cell Tumor Experimental Organism Islet Cell Adenoma Neoplasm
Hypoglycemia	Hypoglycaemia Low Blood Sugar Hypoglycaemia Nos Spontaneous Hypoglycaemia Nondiabetic Hypoglycaemia Hypoglycaemic Disorder Nos Hypoglycaemic Syndrome
Functional Gastric Disease
Diabetes Mellitus	Diabetes
Conn'S Syndrome	Cushing Syndrome Hyperaldosteronism Primary Hyperaldosteronism Hypercortisolism Primary Aldosteronism Cushing'S Syndrome Adrenal Gland Hyperfunction Conn Syndrome Hyperadrenalism Ectopic Acth Syndrome Hyperadrenocorticism Cushing Disease Cushing'S Disease Adrenal Cortex Adenoma Corticotroph Pituitary Adenoma Pituitary Corticotroph Micro-Adenoma Pituitary-Dependent Cushing Syndrome Pituitary Acth Hypersecretion Acth Syndrome, Ectopic Acth-Secreting Pituitary Adenoma Adrenal Hyperfunction Resulting From Pituitary Acth Excess Ectopic Adrenocorticotropic Hormone Syndrome Nodular Primary Adrenocortical Dysplasia Pituitary Dependent Cushing Syndrome Pituitary Cushing Syndrome Pituitary-Dependant Cushing Syndrome Pituitary-Dependant Hypercortisolism Pituitary-Dependant Hypercortisolism Disorder Aldosteronism Primary Acth Syndrome Ectopic Adrenal Cushing'S Syndrome Adrenal Cortical Adenoma Cushing Syndrome Nos Cortisol Hypersecretion Corticoadrenal Hypersecretion Cushing Syndrome Secondary To Ectopic Acth-Secretion Ectopic Cushing Syndrome Hypercortisolism Due To Nonpituitary Tumour Ectopic Acth - [Adrenocorticotropic Hormone] Secretion Ectopic Acth - [Adrenocorticotropic Hormone] Secretion Causing Cushing Syndrome Idiopathic Aldosteronism Aldosteronism Primary Aldosteronism Due To Bilateral Adrenal Hyperplasia Primary Aldosteronism Due To Adrenal Hyperplasia
Nasopharyngitis	Chronic Nasopharyngitis Chronic Rhinopharyngitis
Hyperinsulinemic Hypoglycemia	Nesidioblastosis Islet Cell Hyperplasia Persistent Hyperinsulinemia Hypoglycemia Of Infancy Hyperinsulinemic Hypoglycaemia
Body Mass Index Quantitative Trait Locus 11	OBESITY Obesity, Susceptibility To Leanness, Inherited Obesity, Susceptibility To, Bmiq11 Obesity, Mild, Early-Onset Obesity, Association With Obesity, Early-Onset, Susceptibility To Obesity, Severe Obesity, Severe, And Type Ii Diabetes Obesity, Late-Onset Obesity , Susceptibility To BMIQ11 Obesity Bmiq11 Obesity, Early-Onset Simple Obesity Nos Excess Fat Obesity, Not Elsewhere Classified, Body Mass Index Not Elsewhere Classified Adiposis
Dermatitis, Atopic, 7	ATOD7 Dermatitis, Atopic, Susceptibility To, 7 Atopic Dermatitis 7 Dermatitis, Atopic 7
Barre-Lieou Syndrome	Cervicocranial Syndrome Posterior Cervical Sympathetic Syndrome
Esophageal Adenosquamous Carcinoma
Maturity-Onset Diabetes Of The Young	MODY Maturity Onset Diabetes Mellitus In Young Mason-Type Diabetes Mason Type Diabetes Maturity Onset Diabetes Of The Young Mody Syndrome Diabetes Of The Young, Maturity-Onset

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Approval
Clinical Phase
Pre-clinical Phase

Approval

Bioactive Molecules (6)

製品番号	製品名	製品効果	純度	Rare Diseases
HY-13749	Sitagliptin	Inhibitor	99.94%	Yes
HY-13749A	Sitagliptin phosphate	Inhibitor	99.88%	Yes
HY-13749B	Sitagliptin phosphate monohydrate	Inhibitor	99.83%	Yes
HY-13749AR	Sitagliptin phosphate (Standard)	Inhibitor	99.82%	Unkown
HY-13749E	Sitagliptin hydrochloride	Inhibitor	/	Unkown
HY-13749R	Sitagliptin (Standard)	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (6)

製品番号	製品名	製品効果	純度	Phase
HY-164535	Maridebart cafraglutide		99.24%	Phase 3
HY-P11666	Brenipatide	Agonist	99.29%	Phase 3
HY-P11672	Poterepatide	Agonist	99.78%	Phase 3
HY-P10959	Macupatide	Agonist	99.99%	Phase 2
HY-P10591	Olatorepatide		99.35%	Phase 2
HY-156073	LY3325656	Agonist	/	Phase 1

Pre-clinical Phase

Bioactive Molecules (68)

製品番号	製品名	製品効果	純度	Rare Diseases
HY-P0276	GIP, human	Agonist	99.94%	Unkown
HY-P10138	human GIP(3-30), amide	Antagonist	99.76%	Unkown
HY-P3247	[D-Ala2]-GIP (human)	Agonist	99.95%	Unkown
HY-P0276A	GIP, human TFA	Agonist	99.15%	Unkown
HY-P10735	GIP (mouse)		98.79%	Unkown
HY-P2542	GIP (3-42), human	Antagonist	99.75%	Unkown
HY-P10138A	human GIP(3-30), amide TFA	Antagonist	96.90%	Unkown
HY-P2080B	GIP (1-30) amide,human acetate	Agonist	99.27%	Unkown
HY-P1434	[Pro3]-GIP (mouse)	Antagonist	98.84%	Unkown
HY-P5390A	GIP, rat TFA		99.81%	Unkown
HY-P11285A	LAGIPRA peptide TFA	Agonist	99.86%	Unkown
HY-P3579	Gastric Inhibitory Peptide, porcine		99.12%	Unkown
HY-P10302A	GLP-1R/GIPR agonist-1 (soduim)	Agonist	98.24%	Unkown
HY-P11321A	IUB0271 hydrochloride	Agonist	98.67%	Unkown
HY-P3584A	(Pro3) GIP, human TFA		99.89%	Unkown
HY-P2541A	GIP (1-30) amide, porcine TFA	Agonist	99.14%	Unkown
HY-P10959A	Macupatide acetate	Agonist	99.95%	Unkown
HY-P10929	Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH		99.31%	Unkown
HY-P11271A	Ribupatide TFA	Agonist	99.75%	Unkown
HY-13749AS	Sitagliptin-d4 phosphate	Inhibitor	99.48%	Unkown
HY-P3580A	Acetyl Gastric Inhibitory Peptide (human) TFA		99.70%	Unkown
HY-13749S1	Sitagliptin-d4 hydrochloride	Inhibitor	99.36%	Unkown
HY-153476A	GIP/GLP-1 dual receptor agonist-1 sodium	Agonist	98.33%	Unkown
HY-P10302	GLP-1R/GIPR agonist-1	Agonist	/	Unkown
HY-P10965	Zovaglutide	Agonist	99.25%	Unkown
HY-P11271	Ribupatide	Agonist	98.74%	Unkown
HY-P2080C	GIP (1-30)-Myr	Agonist	/	Unkown
HY-P3255	DA-JC4	Agonist	99.27%	Unkown
HY-P3584	(Pro3) GIP, human	Agonist	99.79%	Unkown
HY-103545	GIP (1-39)	Agonist	/	Unkown
HY-120493	(rel)-AM-6226	Agonist	/	Unkown
HY-120493A	AM-6226	Agonist	/	Unkown
HY-13749S2	Sitagliptin-d4	Inhibitor	/	Unkown
HY-153476	GIP/GLP-1 dual receptor agonist-1	Agonist	98.33%	Unkown
HY-162513	DPP-4-IN-10	Inhibitor	/	Unkown
HY-171302	GLP-1R/GIPR agonist-2	Agonist	/	Unkown
HY-182832	Skim Milk powder	Inhibitor	/	Unkown
HY-187872	Uceglifam		/	Unkown
HY-P0165B	Taspoglutide acetate	Agonist	/	Unkown
HY-P0276F	GIP, Cy5 labeled TFA		/	Unkown
HY-P10952	Astepatide	Agonist	/	Unkown
HY-P10972	GIP (22-51) human		/	Unkown
HY-P11233	Acmopatide	Agonist	/	Unkown
HY-P11270	Relsipatide	Agonist	/	Unkown
HY-P11285	LAGIPRA peptide	Agonist	/	Unkown
HY-P11321	IUB0271	Agonist	/	Unkown
HY-P11674	Zantrutide	Agonist	/	Unkown
HY-P12133	Tapimtrutide	Agonist	/	Unkown
HY-P12134	Zormapatide	Agonist	/	Unkown
HY-P12137	Bilpatide	Agonist	/	Unkown
HY-P12141	DA5-CH		/	Unkown
HY-P1433	[Pro3]-GIP (Rat)	Agonist	/	Unkown
HY-P1731C	Tirzepatide sodium		/	Unkown
HY-P1731CP	Tirzepatide (crude)		/	Unkown
HY-P2080	GIP (1-30) amide,human	Agonist	/	Unkown
HY-P2541	GIP (1-30) amide, porcine	Agonist	/	Unkown
HY-P3577	[Tyr0] Gastric Inhibitory Peptide (23-42), human		/	Unkown
HY-P3578	Gastric Inhibitory Polypeptide (1-30), porcine	Modulator	/	Unkown
HY-P3580	Acetyl Gastric Inhibitory Peptide (human)		/	Unkown
HY-P5390	GIP, rat		/	Unkown
HY-RS01726	C1QTNF1 Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS05434	GIP Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS05535	GNAI2 Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-13749S3	Sitagliptin-d6	Inhibitor	/	Unkown
HY-174832	DPP-4-IN-16	Inhibitor	/	Unkown
HY-184966	PF-07976016	Agonist	98.08%	Unkown
HY-RS16530	Gip Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS22961	Gip Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown

Orthologs Information

生物種	Symbol	由来	ID
Canis familiaris	GIP	VGNC	VGNC:41224
Rattus norvegicus	GIP	RGD	RGD:2709
Macaca mulatta	GIP	VGNC	VGNC:104605
Bos taurus	GIP	VGNC	VGNC:29364
Mus musculus	GIP	MGD	MGI:107504
Felis catus	GIP	VGNC	VGNC:99064
Others	GIP	NCBI